Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Castle Biosciences Inc (CSTL)

Castle Biosciences Inc (CSTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 808,562
  • Shares Outstanding, K 28,007
  • Annual Sales, $ 219,790 K
  • Annual Income, $ -57,470 K
  • EBIT $ 8 M
  • EBITDA $ 15 M
  • 60-Month Beta 0.99
  • Price/Sales 3.56
  • Price/Cash Flow N/A
  • Price/Book 1.77

Options Overview Details

View History
  • Implied Volatility 74.28% ( +1.73%)
  • Historical Volatility 63.44%
  • IV Percentile 58%
  • IV Rank 49.07%
  • IV High 134.09% on 07/15/24
  • IV Low 16.64% on 05/21/24
  • Put/Call Vol Ratio 1.11
  • Today's Volume 57
  • Volume Avg (30-Day) 71
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 1,882
  • Open Int (30-Day) 2,176

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.02
  • Number of Estimates 1
  • High Estimate 0.02
  • Low Estimate 0.02
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +120.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.24 +4.44%
on 11/19/24
35.84 -20.62%
on 11/05/24
-4.19 (-12.84%)
since 10/18/24
3-Month
26.44 +7.60%
on 08/22/24
35.84 -20.62%
on 11/05/24
+1.44 (+5.33%)
since 08/20/24
52-Week
16.97 +67.70%
on 07/05/24
35.84 -20.62%
on 11/05/24
+8.39 (+41.82%)
since 11/20/23

Most Recent Stories

More News
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

Shares of Grifols GRFS lost over 8% on Tuesday after the company’s board refused to endorse Canada-based Brookfield Asset Management’s offer to acquire its outstanding share capital for €6.45 billion...

CTMX : 0.8701 (-2.53%)
CSTL : 28.45 (-1.45%)
GRFS : 8.60 (+1.65%)
SPRO : 1.2000 (+3.45%)
FATE Presents Encourgaing Data From Lupus Study, Stock Gains

Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in its early-stage study on experimental pipeline candidate  FT819.Data showed...

IMCR : 32.42 (-0.43%)
CSTL : 28.45 (-1.45%)
FATE : 2.22 (+1.83%)
SPRO : 1.2000 (+3.45%)
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus

Fate Therapeutics FATE reported a loss of 40 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 42 cents. The company reported a loss of 46 cents per...

IMCR : 32.42 (-0.43%)
CSTL : 28.45 (-1.45%)
ANIP : 55.10 (-1.06%)
FATE : 2.22 (+1.83%)
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up

Axsome Therapeutics, Inc. AXSM incurred an adjusted loss of $1.34 per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of $1.38. The company had incurred a loss...

JAZZ : 119.24 (+2.07%)
CSTL : 28.45 (-1.45%)
ANIP : 55.10 (-1.06%)
AXSM : 94.60 (-0.90%)
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark

SpringWorks Therapeutics, Inc. SWTX incurred a loss of 72 cents per share in the third quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of 76 cents. The company had reported...

IMCR : 32.42 (-0.43%)
CSTL : 28.45 (-1.45%)
ANIP : 55.10 (-1.06%)
SWTX : 37.44 (-1.29%)
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised

Mirum Pharmaceuticals, Inc. MIRM incurred a loss of 30 cents per share in third-quarter 2024, much narrower than the Zacks Consensus Estimate of a loss of 45 cents. The company had reported a loss of 57...

IMCR : 32.42 (-0.43%)
MIRM : 43.69 (+3.80%)
CSTL : 28.45 (-1.45%)
ANIP : 55.10 (-1.06%)
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus

Rocket Pharmaceuticals, Inc. RCKT incurred a loss of 71 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 78 cents. In the year-ago quarter, the company...

FOLD : 9.59 (+0.74%)
IMCR : 32.42 (-0.43%)
CSTL : 28.45 (-1.45%)
RCKT : 13.04 (-0.91%)
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up

Puma Biotechnology, Inc. PBYI reported third-quarter 2024 adjusted earnings of 45 cents per share, which beat the Zacks Consensus Estimate of 35 cents. In the year-ago quarter, the company had reported...

FOLD : 9.59 (+0.74%)
IMCR : 32.42 (-0.43%)
PBYI : 2.84 (+3.65%)
CSTL : 28.45 (-1.45%)
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down

Alkermes plc ALKS reported adjusted earnings from continuing operations of 73 cents per share for third-quarter 2024, which missed the Zacks Consensus Estimate of 78 cents. The company had reported adjusted...

CSTL : 28.45 (-1.45%)
ELEV : 0.5811 (+0.19%)
FATE : 2.22 (+1.83%)
ALKS : 27.91 (+1.56%)
VKTX Beats on Q3 Earnings, Stock Up on Obesity Pipeline Advancements

Viking Therapeutics VKTX reported third-quarter 2024 loss per share of 22 cents, narrower than the Zacks Consensus Estimate of a loss of 24 cents. The company had incurred a loss of 23 cents per share...

FOLD : 9.59 (+0.74%)
VKTX : 51.53 (+0.04%)
CSTL : 28.45 (-1.45%)
FATE : 2.22 (+1.83%)

Business Summary

Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States.

See More

Key Turning Points

3rd Resistance Point 30.06
2nd Resistance Point 29.43
1st Resistance Point 28.94
Last Price 28.45
1st Support Level 27.82
2nd Support Level 27.19
3rd Support Level 26.70

See More

52-Week High 35.84
Fibonacci 61.8% 28.63
Last Price 28.45
Fibonacci 50% 26.40
Fibonacci 38.2% 24.18
52-Week Low 16.97

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar